EUVIMEDEUVIMED entdecken
Leitlinie

NCCN guidelines focus on treatment options for patients with multiple myeloma

Mary Beth Nierengarten

Cancer · 01.09.2025 · 131 (17)

DOI: 10.1002/cncr.70014 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Cancer, online erschienen am 31.08.2025. Verfasst von Mary Beth Nierengarten. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 3 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, recommendations highlight important updates specific to systemic therapy options for those with newly diagnosed or previously treated multiple myeloma. In addition, a persistent PSA level following radical prostatectomy for prostate cancer is associated with a worse prognosis, and outcomes show a reduction in treatment failure associated with dose‐escalated, hypofractionated radiation therapy for localized prostate cancer.

Zitieren

APA

Nierengarten, M. B. (2025). NCCN guidelines focus on treatment options for patients with multiple myeloma. Cancer, 131(17). https://doi.org/10.1002/cncr.70014

Vancouver

Nierengarten MB. NCCN guidelines focus on treatment options for patients with multiple myeloma. Cancer. 2025;131(17). doi:10.1002/cncr.70014

BibTeX
@article{Nierengarten2025,
  author = {Nierengarten, Mary Beth},
  title = {NCCN guidelines focus on treatment options for patients with multiple myeloma},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {17},
  doi = {10.1002/cncr.70014}
}
Kostenlos starten →